HeartFlow has announced that it has launched its next generation of its HeartFlow FFRct system. The result of years of development, the next-generation platform includes major advancements in the process and algorithms HeartFlow uses to calculate fractional flow reserve computed tomography (FFRCT). These technology advancements resulted in the second FDA clearance for HeartFlow’s technology.
A press release report the HeartFlow analysis is the only non-invasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart, enabling clinicians to select an appropriate treatment. The technology, which first received de novo clearance from the FDA in 2014, is also available in Canada, Europe and Japan, and has been used to guide the treatment of thousands of patients globally.
Major enhancements of the new platform include:
- Advanced algorithms and streamlined case processing, which will provide the HeartFlow Analysis results to clinicians more quickly.
- Cloud-based infrastructure using Amazon Web Services (AWS), to ensure that delivery of the HeartFlow service is more secure, robust and scalable.
- Increased security measures to address the needs of healthcare institutions worldwide.
John H Stevens, chairman and CEO of HeartFlow, says: “This is a major milestone for HeartFlow and a crucial advancement as we see increasing adoption of the HeartFlow Analysis around the world. With this next generation platform, HeartFlow will be able to deliver results more quickly and securely to the growing number of physicians using the HeartFlow Analysis to aid in the diagnosis of coronary artery disease.”
